An economic evaluation of a laboratory monitoring program for renin-angiotensin system agents

Medical Decision Making

Volumn 31, Issue 2, 2011, Pages 315-324

  Smith, David H ^a,e   Raebel, Marsha A ^b,e   Chan, K Arnold ^d,e   Johnson, Eric S ^a,e   Petrik, Amanda F ^a,e   Weiss, Jessica R ^a,c   Yang, Xiuhai ^a   Feldstein, Adrianne ^a  

^a CENTER FOR HEALTH RESEARCH   (United States)

^b KAISER PERMANENTE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e HMO Research Network Center for Education and Research in Therapeutics   (United States)

Author keywords

Comparative effectiveness; Cost effectiveness analysis; Evidence synthesis; Health economics

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; COST CONTROL; DRUG EFFECT; ECONOMICS; HUMAN; LABORATORY; METHODOLOGY; MONITORING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

COST SAVINGS; COST-BENEFIT ANALYSIS; HUMANS; LABORATORIES; MONITORING, PHYSIOLOGIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 79953889816     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X10379918     Document Type: Article

References (15)

1. Thomsen LA, Winterstein AG, Sondergaard B, Haugbolle LS, Melander A. Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Ann Pharmacother 2007;41:1411-26. (Pubitemid 47311361)
2. Raebel MA, Lyons EE, Andrade SE, et al. Laboratory monitoring of drugs at initiation of therapy in ambulatory care. J Gen Intern Med 2005;20:1120-6. (Pubitemid 43110262)
3. Raebel MA, McClure DL, Simon SR, et al. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Pharmacoepidemiol Drug Saf. 2007;16:55-64. (Pubitemid 46164976)
4. Raebel MA, Lyons EE, Chester EA, Bodily MA, Kelleher JA, Long CL et al. Improving laboratory monitoring at initiation of drug therapy in ambulatory care: a randomized trial. Arch Intern Med. 2005;165:2395-401. (Pubitemid 41640852)
5. Feldstein AC, Smith DH, Perrin N, et al. Improved therapeutic monitoring with several interventions: a randomized trial. Arch Intern Med. 2006;166:1848-54. (Pubitemid 44455167)
6. Gold M, Siegel J, Russel L, Weinstein M. Cost Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
7. Brenner B, Levine S. Brenner and Rector's The Kidney. 8th ed. Philadelphia: Saunders; 2008.
8. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004;351: 585-92.
9. Desai AA, Baras J, Berk BB, et al. Management of acute kidney injury in the intensive care unit: a cost-effectiveness analysis of daily vs alternate-day hemodialysis. Arch Intern Med. 2008; 168:1761-7.
10. HCUPnet, Healthcare Cost and Utilization Project. Agency for Healthcare Research and Quality, Rockville, MD. http://hcupnet. ahrq.gov/. Accessed 2008 August 5.
11. Localio AR, Lawthers AG, Brennan TA, et al. Relation between malpractice claims and adverse events due to negligence. Results of the Harvard Medical Practice Study III. N Engl J Med. 1991;325:245-51.
12. Studdert DM, Mello MM, Gawande AA, et al. Claims, errors, and compensation payments in medical malpractice litigation. N Engl J Med. 2006;354:2024-33.
13. Billings J, Dixon J, Mijanovich T, Wennberg D. Case finding for patients at risk of readmission to hospital: development of algorithm to identify high risk patients. BMJ. 2006;333:327.
14. Rothman K, Greenland S. Modern Epidemiology. 2nd ed. Boston: Lippincott Williams & Wilkins; 1998.
15. Smith DH, Feldstein AC, Perrin NA, et al. Improving laboratory monitoring of medications: an economic analysis alongside a clinical trial. Am J Manag Care 2009 May; 15(5): 281-28